Differentiation of human embryonic stem cells into pancreatic endocrine cells

• US 10,208,288 B2
• Filed: 11/01/2016
• Issued: 02/19/2019
• Est. Priority Date: 06/08/2012
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Rezania, Alireza
• Primary Examiner(s): Lankford, Blaine
• Application Number:
  US15/340,418
• Publication Number:
  US 20170044499A1
• Time in Patent Office: 840 Days
• Field of Search: None
• CPC Class Codes: C12N 2501/50 Cell markers; Cell surface determinants
• CPC Class Codes: C12N 2501/998 Proteins not provided for elsewhere
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention provides methods to promote differentiation of pancreatic endoderm cells to pancreatic endocrine rich clusters and to enhance insulin expression in hormone-expressing cells.

Claims

1. A method of differentiating pancreatic endoderm cells into pancreatic hormone-expressing cells comprising culturing the pancreatic endoderm cells with an Ephrin ligand, wherein the method induces insulin expression.

2. The method of claim 1, wherein culturing the pancreatic endoderm cells with the Ephrin ligand also enhances expression of NKX6.1.

3. The method of claim 2, wherein culturing the pancreatic endoderm cells with an Ephrin ligand enhances expression of insulin and NKX6.1 in the pancreatic endoderm cells when compared with the expression of insulin and NKX6.1 in non-treated pancreatic endoderm cells.

4. The method of claim 3, wherein the pancreatic endoderm cells do not substantially express CDX2 or SOX2.

5. The method of claim 4, wherein the pancreatic endoderm cells express approximately about less than 10% CDX2 or SOX2.

6. The method of any one of claims 1 to 5, wherein the Ephrin ligand is Ephrin A3 or Ephrin A4.

7. The method of claim 6, wherein the pancreatic endoderm cells are obtained by a stepwise differentiation of pluripotent stem cells.

8. The method of claim 7, wherein the pluripotent stem cells are human embryonic pluripotent stem cells.

9. The method of claim 7, wherein the stepwise differentiation comprises differentiating pluripotent stem cells in definitive endoderm cells.

10. The method of claim 7, wherein the stepwise differentiation comprises:

differentiating pluripotent stem cells into definitive endoderm cells;

differentiating the definitive endoderm cells into primitive gut tube cells;

differentiating the primitive gut tube cells into foregut cells;

differentiating the foregut cells into pancreatic precursor cells; and

differentiating the pancreatic precursor cells into pancreatic endoderm cells.

11. The method of claim 1, wherein the pancreatic endoderm cells are human pancreatic endoderm cells.

12. A method of differentiating pancreatic endoderm cells into pancreatic endocrine cells comprising treating the pancreatic endoderm cells with an Ephrin ligand.

13. The method of claim 12, wherein the Ephrin ligand is Ephrin A3.

14. The method of claim 12, wherein the Ephrin ligand is Ephrin A4.